China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2018
-- 1Q18 Added 22,523 New Subscribers
-- 1Q18 Revenues Up 29.6% YOY to RMB224.2 Million ($33.1 Million)
-- 1Q18 Operating Income Reached RMB83.0 Million ($12.2 Million)
-- Conference Call to be Held on August 24, 2017 at 8:00 a.m. ET
HONG KONG, Aug. 23, 2017 /PRNewswire/ -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the first quarter of fiscal 2018 ended June 30, 2017.
First Quarter of Fiscal 2018 Highlights
-- Revenues for the first quarter of fiscal 2018 increased by 29.6% to
RMB224.2 million ($33.1 million) from RMB173.0 million in the prior year
period.
-- New subscribers and accumulated subscriber base were 22,523 and
597,175(1), respectively.
-- Gross profit increased to RMB179.4 million ($26.5 million) from RMB135.5
million in the prior year period.
-- Gross margin increased to 80.0% from 78.4% in the prior year period.
-- Operating income increased to RMB83.0 million ($12.2 million) from
RMB52.1 million in the prior year period.
-- Operating income before depreciation and amortization and share-based
compensation expenses was RMB92.3 million ($13.6 million), up 15.7% from
RMB79.8 million in the prior year period.(2)
-- Interest expense decreased to RMB3.3 million ($0.5 million) compared to
RMB28.8 million in the prior year period, following the conversion of
all outstanding convertible notes.
-- Net income attributable to the Company's shareholders amounted to
RMB69.1 million ($10.2 million) from RMB15.7 million in the prior year
period.
-- Net cash provided by operating activities for the first quarter of
fiscal 2018 amounted to RMB226.4 million ($33.4 million).
"In the first quarter of fiscal 2018, we recorded 22,523 new subscribers, representing a year-over-year growth of 35.4%. The strong growth was mainly due to our ongoing efforts to enhance our sales team and the more effective and precise sales and marketing strategy. During this quarter, the majority of our new subscribers still came from the Guangdong market and the Beijing market performed steadily as expected." said Ms. Ting Zheng, Chief Executive Officer of China Cord Blood Corporation.
"In the reporting period, the National Health and Family Planning Commission and five other ministries in China collectively issued the "13(th) Five-Year Plan - A Specific Program for Health and Health Science and Technology Innovation"(3), which signals their full support to the stem cell and regenerative medicine industry and provided clarity on regulations for the clinical applications of biotherapies. At the same time, the China Maternal and Child Health Association formed its Umbilical Cord Blood Application Committee in Beijing. We believe such developments will be beneficial to the long-term development of the PRC cord blood banking industry. In the near term, we will continue to explore various sales and marketing tactics to improve demand and expand revenue sources to offset the negative impact of low consumer sentiment and few newborns in certain regions of the PRC."
Summary -- First Quarter Ended June 30, 2016 and 2017
Three Months Ended June 30,
---------------------------
2016 2017
---- ----
(in thousands) RMB RMB US$
Revenues 172,952 224,222 33,074
Gross Profit 135,519 179,440 26,468
Operating Income4 52,135 82,961 12,238
Interest Expense (28,833) (3,257) (480)
Net Income Attributable to the Company's 15,722 69,135 10,198
Shareholders
Earnings per Ordinary Share 0.22 0.62 0.09
- Basic and Diluted5
(RMB/US$)
Revenue Breakdown (%)
Processing Fees 61.8% 65.6%
Storage Fees 38.2% 34.4%
New Subscribers (persons) 16,637 22,523
Total Accumulated Subscribers (persons) 520,905 597,175(1)
Summary -- Selected Cash Flow Statement Items
Three Months Ended June 30,
---------------------------
2016 2017
---- ----
(in thousands) RMB RMB US$
Net cash provided by operating activities 131,014 226,417 33,398
Net cash used in investing activities (79,129) (10,663) (1,573)
Net cash provided by financing activities - - -
First Quarter of Fiscal 2018 Financial Results
REVENUES. Revenues increased by 29.6% to RMB224.2 million ($33.1 million) in the first quarter of fiscal 2018 from RMB173.0 million in the prior year period. The increase was mostly driven by the strong growth in new subscriber sign-ups of 22,523 during the quarter.
Revenues generated from processing fees and other services in the first quarter of fiscal 2018 were RMB147.0 million ($21.7 million), up 37.5% from RMB106.9 million in the prior year period. Revenues generated from processing fees accounted for 65.6% of total revenues.
Revenues generated from storage fees increased by 16.8% to RMB77.2 million ($11.4 million) in the first quarter of fiscal 2018 from RMB66.1 million in the prior year period. The increase was due to the increase of the accumulated subscriber base, which grew to 597,175(1) by the end of June 2017. Storage fee revenues accounted for 34.4% of total revenues.
GROSS PROFIT. Gross profit for the first quarter of fiscal 2018 increased by 32.4% to RMB179.4 million ($26.5 million) from RMB135.5 million in the prior year period. Gross margin improved to 80.0% from 78.4% in the prior year period, benefiting from economy of scale.
OPERATING INCOME. Operating income for the first quarter of fiscal 2018 increased to RMB83.0 million ($12.2 million) from RMB52.1 million in the prior year period. Driven by the increase in gross profit partly netted by higher operating expenses, operating margin increased to 37.0% from 30.1% in the prior year period. Depreciation and amortization expenses for the reporting quarter were RMB12.8 million ($1.9 million), compared to RMB12.6 million in the prior year period. Net share-based compensation expense related to the Company's restricted share units ("RSUs") scheme recorded a reversal of RMB3.4 million ($0.5 million) for the first quarter of fiscal 2018. Such reversal was resulted from the write back of previously recognized share-based compensation expense due to the cancellation of RSUs forfeited on the resignation of one of the grantees, partially offset by additional expense charged on the RSUs granted during the first quarter. Comparatively, share-based compensation expense was RMB15.1 million in the prior year period. Operating income before depreciation and amortization and share-based compensation expenses totaled RMB92.3 million ($13.6 million), representing a 15.7% increase from RMB79.8 million in the prior year period.(2)
Research and Development Expenses.
Research and development expenses
were RMB2.7 million ($0.4 million) in
the first quarter of fiscal 2018,
compared to RMB1.9 million in the
prior year period.
Sales and Marketing Expenses. Sales
and marketing expenses for the first
quarter amounted to RMB43.5 million
($6.4 million), compared to RMB38.2
million in the prior year period. Our
efforts to strengthen our sales team
and promote our service to target
clients in a more comprehensive
manner led to the increase. As a
percentage of revenues, sales and
marketing expenses were 19.4%, down
from 22.1% in the prior year period.
General and Administrative Expenses.
General and administrative expenses
for the first quarter increased to
RMB50.4 million ($7.4 million) from
RMB43.2 million in the prior year
period. General and administrative
expenses as the percentage of revenues
remained in check at 22.5%, down from
25.0% in the prior year period.
OTHER INCOME AND EXPENSES.
Interest Expense. Interest
expense was down from
RMB28.8 million to RMB3.3
million ($0.5 million) in
the current period. The
decrease was mainly because
of the conversion of the
Company's convertible notes
into ordinary shares in
early April 2017 and no
convertible notes related
interest expense was
incurred thereafter.
NET INCOME ATTRIBUTABLE TO THE COMPANY'S SHAREHOLDERS. As a result of the increase in operating income and the decline in interest expense, income before income tax for the first quarter of fiscal 2018 increased significantly to RMB85.7 million ($12.6 million) from RMB27.9 million in the prior year period. Income tax expense for the first quarter of fiscal 2018 was RMB15.7 million ($2.3 million), compared to RMB11.7 million in the prior year period. Net income attributable to the Company's shareholders for the first quarter of fiscal 2018 reached RMB69.1 million ($10.2 million) from RMB15.7 million in the prior year period. Net margin for the first quarter of fiscal 2018 improved to 30.8% from 9.1% in the prior year period.
EARNINGS PER SHARE. Basic and diluted earnings per ordinary share for the first quarter of fiscal 2018 increased to RMB0.62 ($0.09)(5) from RMB0.22 in the prior year period.
LIQUIDITY. As of June 30, 2017, the Company had cash and cash equivalents of RMB3,724.7 million ($549.4 million) with aggregate current and non-current deferred revenues amounted to RMB1,995.2 million ($294.3 million). Net cash provided by operating activities for the first quarter of fiscal 2018 amounting to RMB226.4 million ($33.4 million).
Conference Call
The Company will host a conference call at 8:00 a.m. ET on Thursday, August 24, 2017 to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties can access the audio webcast through the Company's IR website at http://ir.chinacordbloodcorp.com. A replay of the webcast will be accessible two hours after the conference call and available for three weeks at the same URL above. Listeners can also access the call by dialing 1-719-325-2213 or 1-866-564-2842 for US callers, or +852-3008-1527 for Hong Kong callers, access code: 2659383.
(1) During the three months ended
June 30, 2017, 22,523 new
subscribers were recruited and
the Company reclassified 388
private cord blood units as
donated cord blood units after
the Company determined that the
recoverability of these prior
private cord blood banking
subscribers was low therefore
the Company terminated their
subscription services according
to the subscription contracts.
These units are being treated as
if they were donated cord blood
units and will be part of the
Company's non-current
inventories. Hence the net
accumulated subscriber base was
597,175 as of June 30, 2017.
(2) See exhibit 3 of this press
release for a reconciliation of
operating income to exclude the
non-cash items related to the
depreciation and amortization and
share-based compensation expenses
to the comparable financial
measure prepared in accordance
with U.S. generally accepted
accounting principles ("U.S.
GAAP").
(3) http://www.most.gov.cn/mostinfo/xinxifenlei/fgzc/gfxwj/gfxwj2017/201706/t20170614_133527.htm
4 The reported operating
income for the three
months ended June 30,
2016 and 2017 included
the following:
(i) Depreciation and
amortization expenses for the
three months ended June 30,
2016 and 2017 were RMB12.6
million and RMB12.8 million
($1.9 million); and
(ii) As of June 30, 2017, a total
of 7,300,000 RSUs were issued and
outstanding under the Company's
RSU scheme, subject to certain
performance conditions. Share-
based compensation expenses
related to this RSU scheme were
RMB15.1 million for the three
months ended June 30, 2016. During
the three months ended June 30,
2017, a net reversal of RMB3.4
million ($0.5 million) share-
based compensation expense was
recorded.
5 Out of 7,300,000 RSUs issued
and outstanding as of June 30,
2017, 7,080,000 ordinary shares
("Shares") were issued and
deposited into a trust
sponsored and funded by the
Company ("Trust"), and will be
transferred to respective
executives, directors and key
employees (or their designated
nominees) under the Company's
RSU scheme when the performance
conditions are met. The Trust
facilitates the granting (and
subsequent vesting) of
incentive RSUs and holds such
Shares for the benefit of such
executives, directors and key
employees as a class. Taking
into account of such Shares, in
addition to 113,524,742
outstanding shares (73,003,248
outstanding shares for the
three months ended June 30,
2016), basic and diluted
earnings per ordinary share
would be RMB0.20 and RMB0.59
($0.09) for the three months
ended June 30, 2016 and 2017,
respectively.
Use of Non-GAAP Financial Measures
GAAP results for the three months ended June 30, 2017 include non-cash items related to the depreciation and amortization and share-based compensation expenses. To supplement the Company's unaudited condensed consolidated financial statements presented on a U.S. GAAP basis, the Company has provided adjusted financial information excluding the impact of these items in this press release. The non-GAAP financial measure represents non-GAAP operating income. Such adjustment is a departure of U.S. GAAP; however, the Company's management believes that these adjusted measures provide investors with a better understanding of how the results relate to the Company's historical performance. Also, management uses non-GAAP operating income as a measurement tool for evaluating actual operating performance compared to budget and prior periods. These adjusted measures should not be considered an alternative to operating income, or any other measure of financial performance or liquidity presented in accordance with U.S. GAAP. These measures are not necessarily comparable to a similarly titled measure of another company. A reconciliation of the adjustments to U.S. GAAP results appears in exhibit 3 accompanying this press release. This additional adjusted information is not meant to be considered in isolation or as a substitute for U.S. GAAP financials. The adjusted financial information that the Company provides also may differ from the adjusted information provided by other companies.
About China Cord Blood Corporation
China Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Under current PRC government regulations, only one licensed cord blood banking operator is permitted to operate in each licensed region and no new licenses will be granted before 2020 in addition to the seven licenses authorized as of today. China Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services. For more information, please visit our website at http://www.chinacordbloodcorp.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company's future financial performance. The Company has attempted to identify forward-looking statements by terminology including "anticipates", "believes", "expects", "can", "continue", "could", "estimates", "intends", "may", "plans", "potential", "predict", "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to conform these statements to actual results, unless required by law.
The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about the Company's businesses and business environments. These statements reflect the Company's current views with respect to future events and are not a guarantee of future performance. Actual results of the Company's operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: continued compliance with government regulations regarding cord blood banking in the People's Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments (including the relaxation of China's one child policy) in the PRC and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company's different pricing and payment options and reaction to the introduction of the Company's premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company's ability to effectively manage its growth, including implementing effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a "reverse merger" with an operating company based in China, as well as general economic conditions; the proposed transactions between an affiliate of Golden Meditech Holdings Limited and Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (limited partnership); and other relevant risks detailed in the Company's filings with the Securities and Exchange Commission in the United States.
This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the period ending June 30, 2017 were made at the noon buying rate of RMB6.7793 to $1.00 on June 30, 2017 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. China Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.
For more information, please contact:
China Cord Blood Corporation
Investor Relations Department
Tel: (+852) 3605-8180
Email: ir@chinacordbloodcorp.com
ICR, Inc.
William Zima
Tel: (+86) 10-6583-7511
U.S. Tel: (646) 405-5185
Email: William.zima@icrinc.com
EXHIBIT 1
CHINA CORD BLOOD CORPORATION
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
As of March 31 and June 30, 2017
--------------------------------
March 31, June 30,
2017 2017
RMB RMB US$
(in thousands except share data)
ASSETS
Current assets
Cash and cash equivalents 3,510,264 3,724,699 549,422
Accounts receivable, less allowance for doubtful
accounts (March 31, 2017: RMB46,858;
June 30, 2017: RMB53,475 (US$7,888)) 112,533 111,469 16,443
Inventories 30,987 35,794 5,280
Prepaid expenses and other receivables 17,524 17,397 2,566
------ ------ -----
Total current assets 3,671,308 3,889,359 573,711
Property, plant and equipment, net 551,434 545,684 80,493
Non-current deposits 237,487 237,810 35,079
Non-current accounts receivable, less allowance
for doubtful accounts (March 31, 2017: RMB70,744;
June 30, 2017: RMB68,386 (US$10,087)) 135,148 129,498 19,102
Inventories 68,775 69,497 10,251
Intangible assets, net 106,686 105,531 15,567
Available-for-sale equity securities 200,790 184,829 27,264
Other investment 189,129 189,129 27,898
Deferred tax assets 22,155 24,098 3,555
------ ------ -----
Total assets 5,182,912 5,375,435 792,920
========= ========= =======
LIABILITIES
Current liabilities
Convertible notes, net 1,031,154 - -
Accounts payable 11,060 14,251 2,102
Accrued expenses and other payables 65,162 85,003 12,539
Deferred revenue 323,690 347,074 51,196
Amount due to related party 4,679 10,459 1,543
Income tax payable 11,383 13,641 2,012
------ ------ -----
Total current liabilities 1,447,128 470,428 69,392
Non-current deferred revenue 1,569,579 1,648,138 243,113
Other non-current liabilities 302,233 315,725 46,572
Deferred tax liabilities 21,423 21,274 3,138
Total liabilities 3,340,363 2,455,565 362,215
--------- --------- -------
EQUITY
Shareholders' equity of China Cord Blood
Corporation
Ordinary shares
- US$0.0001 par value, 250,000,000 shares
authorized, 73,140,147 shares issued and
73,003,248 shares outstanding as of March 31, 50 78 12
2017 and 113,661,641 shares issued and
113,524,742 shares outstanding as of June 30, 2017
Additional paid-in capital 936,417 1,967,406 290,208
Treasury stock, at cost (March 31 and June 30,
2017: 136,899 shares, respectively)
(2,815) (2,815) (415)
Accumulated other comprehensive income 24,428 772 114
Retained earnings 879,775 948,910 139,972
------- ------- -------
Total equity attributable to China Cord Blood
Corporation 1,837,855 2,914,351 429,891
Non-controlling interests 4,694 5,519 814
----- ----- ---
Total equity 1,842,549 2,919,870 430,705
--------- --------- -------
Total liabilities and equity 5,182,912 5,375,435 792,920
========= ========= =======
EXHIBIT 2
CHINA CORD BLOOD CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
For the Three Months Ended June 30, 2016 and 2017
-------------------------------------------------
Three months ended June 30,
---------------------------
2016 2017
RMB RMB US$
(in thousands except per share data)
Revenues 172,952 224,222 33,074
Direct costs (37,433) (44,782) (6,606)
------- ------- ------
Gross profit 135,519 179,440 26,468
Operating expenses
Research and development (1,949) (2,679) (394)
Sales and marketing (38,192) (43,450) (6,409)
General and administrative (43,243) (50,350) (7,427)
------- ------- ------
Total operating expenses (83,384) (96,479) (14,230)
------- ------- -------
Operating income 52,135 82,961 12,238
------ ------ ------
Other (expenses)/income, net
Interest income 4,277 4,827 712
Interest expense (28,833) (3,257) (480)
Foreign currency exchange gains 135 1 -
Others 152 1,149 169
--- ----- ---
Total other (expenses)/income, net (24,269) 2,720 401
------- ----- ---
Income before income tax 27,866 85,681 12,639
Income tax expense (11,676) (15,721) (2,319)
------- ------- ------
Net income 16,190 69,960 10,320
Net income attributable to non-controlling interests (468) (825) (122)
---- ---- ----
Net income attributable to China Cord
Blood Corporation's shareholders 15,722 69,135 10,198
====== ====== ======
Earnings per share:
Attributable to ordinary shares
- Basic 0.22 0.62 0.09
==== ==== ====
- Diluted 0.22 0.62 0.09
==== ==== ====
Other comprehensive losses,
net of nil income taxes
- Foreign currency translation adjustments (6,960) (11,731) (1,730)
- Unrealized holding losses in
available-for-sale equity securities
(6,470) (11,925) (1,759)
------ ------- ------
Total other comprehensive losses (13,430) (23,656) (3,489)
------- ------- ------
Comprehensive income 2,760 46,304 6,831
===== ====== =====
Comprehensive income attributable to
non-controlling interests (468) (825) (122)
---- ---- ----
Comprehensive income attributable to
China Cord Blood Corporation's shareholders 2,292 45,479 6,709
===== ====== =====
EXHIBIT 3
CHINA CORD BLOOD CORPORATION
RECONCILIATION OF NON-GAAP OPERATING INCOME
For the Three Months Ended June 30, 2016 and 2017
-------------------------------------------------
Three months ended June 30,
---------------------------
2016 2017
---- ----
RMB RMB US$
(in thousands)
GAAP amount of operating income 52,135 82,961 12,238
Depreciation and amortization expenses6 12,584 12,752 1,881
Share-based compensation expense7 15,059 (3,438) (507)
------ ------ ----
Non-GAAP operating income 79,778 92,275 13,612
====== ====== ======
6 Depreciation and amortization expenses relate to property, plant and equipment and intangible assets
respectively.
7 Share-based compensation expense relates to the Company's RSU scheme, in which 7,300,000 RSUs were
issued and outstanding as of June 30, 2017.
View original content:http://www.prnewswire.com/news-releases/china-cord-blood-corporation-reports-financial-results-for-the-first-quarter-of-fiscal-2018-300508286.html
SOURCE China Cord Blood Corporation
